Saniona AB (SANION) AI Stock Analysis

• Market Cap: kr2.26B
• Dividend Yield: N/A
• Average Volume (3M): 1.06M
• Price to Earnings (P/E): 9.6
• Beta (1Y): -0.15
• Revenue Growth: 2687.51%
• EPS Growth: N/A
• Country: SE
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 138,030,140
• 10 Day Avg. Volume: 913,988
• 30 Day Avg. Volume: 1,064,614
• PEG Ratio: 0.39
• Price to Book (P/B): 4.30
• Price to Sales (P/S): 6.29
• P/FCF Ratio: 13.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr11.00M

• Rating: 59 Neutral
• Price Target: kr15.00 ▼(-28.91% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is held back primarily by weak technicals (strong downtrend with negative momentum), partially offset by improved recent financial performance (profitability and cash flow turning positive, debt-free balance sheet) and an attractive P/E valuation.

Positive Factors

Improved Cash Generation

The firm delivered positive operating and free cash flow in 2024–2025 after years of burn, which materially improves sustainability. Durable cash generation reduces near-term financing dependency, supports R&D pacing and partnering negotiation leverage, and underpins multi‑quarter operational stability.

Negative Factors

Revenue Volatility

Material swings in revenue across consecutive years indicate heavy reliance on lumpy milestone or licensing receipts. That uneven top‑line makes margins and cash generation difficult to predict, complicates multi‑quarter planning and raises the chance that profitability proves transitory without repeatable revenue streams.

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhi...

Read more

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhi...

How the Company Makes Money

Saniona AB generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates in exchange for milestone payments and royalties on fut...

Read more

Saniona AB generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates in exchange for milestone payments and royalties on fut...

Saniona AB Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	434.40M	334.67M	16.84M	15.28M	10.48M
Gross Profit	274.72M	329.58M	11.78M	10.81M	5.85M
EBITDA	281.45M	251.90M	-68.28M	-198.41M	-398.86M
Net Income	284.67M	188.71M	-95.81M	-245.36M	-410.90M
Balance Sheet
Total Assets	679.74M	339.73M	64.14M	153.70M	440.25M
Cash, Cash Equivalents and Short-Term Investments	580.82M	303.26M	30.96M	111.71M	356.86M
Total Debt	0.00	10.50M	71.41M	81.52M	99.77M
Total Liabilities	44.58M	107.92M	86.08M	100.99M	158.25M
Stockholders Equity	635.16M	231.82M	-21.94M	52.71M	282.00M
Cash Flow
Free Cash Flow	200.30M	249.07M	-85.66M	-282.52M	-346.52M
Operating Cash Flow	273.86M	249.20M	-85.53M	-281.54M	-345.04M
Investing Cash Flow	-77.62M	-124.00K	-129.00K	6.84M	43.16M
Financing Cash Flow	108.19M	23.25M	-7.97M	-20.52M	50.60M

Saniona AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 21.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Neutral. The current price of 21.1 is above the 20-day moving average (MA) of 15.54, above the 50-day MA of 20.40, and above the 200-day MA of 15.68, indicating a neutral trend. The MACD of -1.00 indicates Negative momentum. The RSI at 46.19 is Neutral, neither overbought nor oversold. The STOCH value of 79.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SANION.

Saniona AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	59 Neutral	kr2.26B	9.60	167.77%	―	2687.51%	―
SYNACT	56 Neutral	kr971.68M	-10.42	-58.41%	―	―	48.14%
CANTA	55 Neutral	kr1.00B	-8.03	81.19%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCO	49 Neutral	kr542.99M	-4.37	―	―	131.20%	32.28%
XBRANE	46 Neutral	kr144.03M	121.99	-16.90%	―	4.64%	―
XSPRAY	45 Neutral	kr1.29B	-7.05	-35.03%	―	―	25.14%

Saniona AB Corporate Events